PTGFRN and mesothelioma: Further in vivo studies are required to explore different doses of the ADC, as well as investigating the effect of 33B7-ADC on mouse xenografts models of medulloblastoma and mesothelioma, which we have shown to express PTGFRN, in order to investigate the efficacy of targeting PTGFRN for these cancers with unmet needs.